Please login to the form below

psoriatic arthritis

This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Xeljanz is approved in the US for use in adults with rheumatoid arthritis (RA) who have not responded well to methotrexate treatment. ... It is also approved to treat patients with psoriatic arthritis who have not responded well to prior methotrexate

Latest news

AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as studies in psoriatic arthritis and atopic dermatitis ... Novartis’ drug is currently approved for adults with
J&J splashes $750m on anti-inflammatory drug bermekimab

J&J is already a leader in the immunology market, and recently filed its next-generation IL-23 inhibitor Tremfya in psoriatic arthritis (PsA) with the European Medicines Agency.
Amgen raises forecasts after closing $13.4bn Otezla deal

Otezla grew 26% to reach $1.6bn in sales across its psoriasis, psoriatic arthritis and Behçet's disease indications last year, and has continued its expansion this year with a tally
Novartis’ Cosentyx misses the mark in Humira head-to-head

Narrowly missed statistical significance for superiority. Novartis’ Cosentyx (secukinumab) failed to show significant superiority over AbbVie’s Humira (adalimumab) in a head-to-head trial in psoriatic arthritis (PsA). ... We will assess the EXCEED
Pfizer raises forecast following growth of biopharma business

Aside from its oncology business, Pfizer also saw growth of its global revenues for Xeljanz to $599m due to continued volume growth in the rheumatoid arthritis indication and the recent launch ... for psoriatic arthritis in the US.

More from news
Approximately 15 fully matching, plus 121 partially matching documents found.

Latest Intelligence

Helping patients to help themselves – how pharma can get more from patient support programmes

For example, when developing a patient support programme for patients with Ankylosing Spondylitis and Psoriatic Arthritis, earthware identified that, for newly diagnosed patients, the impact of receiving the diagnosis on their
Innovation in a digital context is not about technology – it’s about people

Putting it into practice. This process is well illustrated through our development of Psoriasis360.co.uk, a website to support people with psoriatic disease. ... We have also been continuously developing new content based on patients’ needs: an
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular
Drug launches to watch in 2019

Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.
The good, the bad and the ugly

Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

Changing healthcare, one film at a time

Millefeuille’ [ IMDB] explores the issues of isolation and restriction people with psoriasis and psoriatic arthritis struggle with, and the degree to which they are self-imposed, through the character of Élodie –
emotive adds to medical team with new Scientific Lead and Associate Medical Writer

Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
Lucid win PMEA Support Agency of the Year 2016

management of psoriatic arthritis.Judges’ comments: “In taking a different approach, this work stands out from the many support programmes already out there.
Lucid make the shortlist in all of the four categories they entered for the PMEA programme 2016

um: Changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic arthritis. .
Millefeuille

This story of hope charts Élodie’s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. This story of hope charts Élodie’s physical and mental struggles

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Principal Medical Writer: Varies on experience

Account Management: Competitive Salary Offered

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

PMHub

Add my company

Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....